FDA clears Zyrtec line extension
This article was originally published in The Tan Sheet
Executive Summary
McNeil Consumer Healthcare gains regulatory approval for Zyrtec Allergy orally disintegrating tablets (cetirizine 10 mg). In a Sept. 3 1letter, FDA's Division of Nonprescription Clinical Evaluation green-lights McNeil's new drug application, submitted in November 2009, for 6-, 12-, 24- and 66-count cartons of the OTC. The Johnson & Johnson subsidiary has fulfilled the pediatric study requirements for the Zyrtec extension, FDA adds. J&J/McNeil declined to comment on when the tablets will launch. With generics readily available, Zyrtec and other brands seek innovative delivery formats to stay a step ahead of private label (2"The Tan Sheet" Oct. 6, 2008)
You may also be interested in...
Fending Off Private Label Competition: Innovation Is Key
Innovative drug delivery, claims and packaging are keys to defending name brands from private label competition as consumers grow increasingly price sensitive
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.